Highton J, Grahame R
J Rheumatol Suppl. 1980;6:125-31.
A double-blind within-patient crossover trial compared the new nonsteroidal antiinflammatory agent benoxaprofen with ibuprofen in the treatment of osteoarthritis in 31 patients. Both benoxaprofen (600 mg once daily) and ibuprofen (400 mg qid) improved measurements of pain, stiffness, range of movement, mobility, patient preference, and overall assessment. However, the improvement was statistically significant only for pain at rest and range of knee movement for both drugs and for range of hip movement (N = 8) for ibuprofen. There was no statistically significant difference between treatments with the 2 drugs. Six patients taking benoxaprofen reported skin irritation on exposure to sunlight.
一项双盲患者自身交叉试验,将新型非甾体抗炎药贝诺洛芬与布洛芬用于31例骨关节炎患者的治疗比较。贝诺洛芬(每日一次,600毫克)和布洛芬(每日四次,400毫克)均改善了疼痛、僵硬、活动范围、行动能力、患者偏好及总体评估的测量指标。然而,仅在静息时的疼痛、两种药物的膝关节活动范围以及布洛芬的髋关节活动范围(N = 8)方面,改善具有统计学意义。两种药物治疗之间无统计学显著差异。6例服用贝诺洛芬的患者报告在暴露于阳光下时出现皮肤刺激。